Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients

Withdrawn

• Conditions: Rheumatoid Arthritis; COVID
• Interventions: Drug: Traditional antirheumatic drugs

• Registration Number: NCT04434118
• Lead Sponsor: Sadat City University

Brief Summary

Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-20
• Study First Submitted: 2020-06-13
• Study First Submitted QC: 2020-06-15
• Study First Posted: 2020-06-16
• Primary Completion: 2021-12-30
• Study Completion: 2021-12-30
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-03
• Last Update Posted: 2022-05-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Data of all definite cases of RA were collected and reviewed from complete medical records of patients by a team that included 2 trained physicians using a pretested data collection form.

Exclusion Criteria

• The exclusion criteria were included incomplete medical records or those with difficulty to communicate with the patients.
• Patients with acute lethal organ injury (e.g., acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, or acute stroke)
• Patients with decompensated or end stage chronic organ dysfunction (e.g., decompensated cirrhosis, decompensated chronic renal insufficiency, or severe congestive heart failure), diabetes mellitus, data of pregnant females, acquired immune deficiency syndrome (aids), and leukemia or other malignancies.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Rheumatoid Arthritis with COVID-19	Traditional antirheumatic drugs	-
Rheumatoid Arthritis without COVID-19	Traditional antirheumatic drugs	-

Primary Outcome Measures

Name	Time	Method
The risk of COVID-19 infection among RA patients	12 week	Realtion between hydroxychloroquine use and COVID-19 infection

Secondary Outcome Measures

Name	Time	Method
The incidence of hospitalization for Covid-19 patients.	12 week	Number of cases and number of hospitalization days

Trial Locations

Locations (1)

Faculty of Medicine; 🇪🇬 Shibīn Al Kawm, Egypt